HC Wainwright & Co. Initiates Coverage On Cardiol Therapeutics with Buy Rating, Announces Price Target of $9

Cardiol Therapeutics Inc. Class A 0.00%

Cardiol Therapeutics Inc. Class A

CRDL

1.00

0.00%

HC Wainwright & Co. analyst Vernon Bernardino initiates coverage on Cardiol Therapeutics (NASDAQ: CRDL) with a Buy rating and announces Price Target of $9.
Every question you ask will be answered
Scan the QR code to contact us
whatsapp
Also you can contact us via